GSK's consumer healthcare business posts third-quarter growth | Progresiv
The consumer healthcare division of GlaxoSmithKline, which includes brands including Panadol and Aquafresh, has posted 2.5 billion pounds (2.9 billion euros) in sales in the third quarter of the group's financial year. 
This is up 3% on a pro forma basis, at constant exchange rates.
If the positive impact of the merger with the Pfizer consumer healthcare business is included, sales are up 25% for the division in the period.
Reported group sales for the period were up 11% at constant exchange rates (+6% on a pro forma basis), to 9.4 billion pounds (10.89 billion euros).
“GSK has made further good progress in Q3, with sales growth across all three businesses, and we have today upgraded our full-year EPS guidance," commented Emma Walmsley, GSK chief executive.
"We also achieved a significant milestone with the completion of our new Consumer Healthcare Joint Venture with Pfizer, to create a new world leading consumer healthcare business.”
GSK anticipates 2019 adjusted EPS to be flat for the full year, at constant exchange rates. (www.esmmagazine.com)
